Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544095 | 0.90 | THRB (0.31) | — | |
| SCHEMBL16342580 | 0.88 | ALDH1A1 (0.33) | HPGDSMN1; SMN2MAPTTYRCYP19A1 | |
| SCHEMBL15544403 | 0.85 | PSMD10 (0.39) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL15545842 | 0.85 | GUSB (0.45) | SMN1; SMN2MEN1KMT2ACA1CA2 | |
| SCHEMBL16343122 | 0.85 | — | — | |
| SCHEMBL15544042 | 0.83 | PKM (0.38) | HPGDSMN1; SMN2MAPTTYRCYP19A1 | |
| SCHEMBL15544471 | 0.79 | CYP19A1 (0.40) | HPGDSMN1; SMN2MAPTCYP19A1MEN1 | |
| SCHEMBL15545174 | 0.78 | THRB (0.32) | TYRGAA | |
| SCHEMBL16367337 | 0.78 | GUSB (0.31) | — | |
| SCHEMBL15544607 | 0.78 | GUSB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206198-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2020-07-02 | — | — | US | claimed |
| EP-3658136-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | Raia, Valeria (IT) | 2020-06-03 | — | — | EP | claimed |
| WO-2019020663-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2019-01-31 | — | — | WO | claimed |
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| EP-3045912-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| US-10006904-B2 | Rapid quantitative assay to measure CFTR function in a primary intestinal culture model | UMC UTRECHT HOLDING B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| EP-3045912-A1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC Utrecht Holding B.V. (NL) | 2016-07-20 | — | — | EP | disclosed |
| EP-2795322-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2015-12-09 | — | — | EP | disclosed |
| US-20150276719-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-10-01 | — | — | US | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| EP-2793871-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | Auckland Uniservices Limited (NZ) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014007650-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | HPGD 21/4885SMN1; SMN2 4329/4885MAPT 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.